• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Intraday Session

    5/24/23 1:31:45 PM ET
    $APGN
    $BDRX
    $BIOL
    $BIOR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $APGN alert in real time by email

    Gainers

    • Minerva Surgical (NASDAQ:UTRS) shares rose 153.3% to $0.46 during Wednesday's regular session. Trading volume for this security as of 13:30 EST is 82.3 million, which is 14267.1% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $81.4 million.
    • Enveric Biosciences (NASDAQ:ENVB) stock rose 90.52% to $6.0. Trading volume for Enveric Biosciences's stock is 66.1 million as of 13:30 EST. This is 2999.9% of its average full-day volume over the last 100 days. The company's market cap stands at $12.4 million.
    • Zura Bio (NASDAQ:ZURA) shares rose 34.01% to $7.17. As of 13:30 EST, this security is trading at a volume of 13.1 million shares, making up 2966.4% of its average full-day volume over the last 100 days. The company's market cap stands at $228.0 million.
    • Apexigen (NASDAQ:APGN) stock moved upwards by 32.12% to $0.53. Trading volume for this security as of 13:30 EST is 8.7 million, which is 7955.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $13.0 million.
    • China Pharma Holding (AMEX:CPHI) stock rose 20.65% to $0.39. As of 13:30 EST, China Pharma Holding's stock is trading at a volume of 1.2 million, which is 333.4% of its average full-day volume over the last 100 days. The company's market cap stands at $3.7 million.
    • Biora Therapeutics (NASDAQ:BIOR) stock increased by 17.88% to $4.68. Trading volume for this security as of 13:30 EST is 244.3K, which is 175.5% of its average full-day volume over the last 100 days. The company's market cap stands at $55.5 million.

    Losers

    • Biolase (NASDAQ:BIOL) shares fell 42.3% to $0.08 during Wednesday's regular session. As of 13:30 EST, Biolase's stock is trading at a volume of 33.3 million, which is 2090.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $2.5 million.
    • Ocugen (NASDAQ:OCGN) shares decreased by 36.06% to $0.46. As of 13:30 EST, this security is trading at a volume of 32.6 million shares, making up 494.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $104.0 million.
    • T2 Biosystems (NASDAQ:TTOO) stock declined by 30.65% to $0.12. Trading volume for T2 Biosystems's stock is 13.7 million as of 13:30 EST. This is 1681.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $2.4 million. The company's, Q1 earnings came out yesterday.
    • Biodexa Pharmaceuticals (NASDAQ:BDRX) shares declined by 28.38% to $0.14. Biodexa Pharmaceuticals's stock is trading at a volume of 4.3 million shares as of 13:30 EST. This is 106.4% of its average full-day volume over the last 100 days. The company's market cap stands at $2.6 million.
    • Oncorus (NASDAQ:ONCR) stock decreased by 24.8% to $0.18. As of 13:30 EST, Oncorus's stock is trading at a volume of 194.0K, which is 262.9% of its average full-day volume over the last 100 days. The company's market cap stands at $4.8 million. The company's, Q1 earnings came out 2 days ago.
    • CohBar (NASDAQ:CWBR) stock declined by 24.58% to $3.78. Trading volume for this security as of 13:30 EST is 1.4 million, which is 176.5% of its average full-day volume over the last 100 days. The company's market cap stands at $10.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $APGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APGN
    $BDRX
    $BIOL
    $BIOR

    CompanyDatePrice TargetRatingAnalyst
    Ocugen Inc.
    $OCGN
    3/17/2026$12.00Buy
    Canaccord Genuity
    Ocugen Inc.
    $OCGN
    3/11/2026$10.00Outperform
    Oppenheimer
    Zura Bio Limited
    $ZURA
    2/9/2026$15.00Outperform
    Wedbush
    Zura Bio Limited
    $ZURA
    11/4/2024$15.00Outperform
    Leerink Partners
    Ocugen Inc.
    $OCGN
    10/15/2024$4.00Buy
    Maxim Group
    Zura Bio Limited
    $ZURA
    9/5/2024$5.00Neutral
    H.C. Wainwright
    Zura Bio Limited
    $ZURA
    5/3/2024$26.00Overweight
    Piper Sandler
    Biodexa Pharmaceuticals plc American Depositary Shs
    $BDRX
    2/8/2024$8.00Buy
    Ladenburg Thalmann
    More analyst ratings

    $APGN
    $BDRX
    $BIOL
    $BIOR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2025

    Product Development Highlights: Reported positive preclinical results for lead drug candidate EB-003, showing statistically significant improvements in animal models of severe chronic depression and despair and in post-traumatic stress disorder (PTSD) Identified neuroplastogen candidates with potential to promote brain-derived neurotrophic factor (BDNF) signaling, an established therapeutic target for neurodegenerative disease Corporate and Business Development Highlights: Announced the withdrawal of the Post-Grant Review (PGR) petition filed by Gilgamesh Pharmaceuticals against Enveric's issued U.S. Patent No. 12,138,276, which appears relevant to the bretisilocin (GM-2505) mol

    3/27/26 5:40:00 PM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Preliminary Results for the Year Ended 31 December 2025

    March 27, 2026 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company" or, together with its subsidiaries, the "Group") Preliminary Results for the Year Ended 31 December 2025 Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, announces its audited preliminary results for the year ended 31 December 2025. For more information, please contact: Biodexa Pharmaceuticals PLC Stephen Stamp, CEO Fiona Sharp, CFOTel: +44 (0)29 2048 0180www.biodexapharma.com About Biodexa The Company's lead development programs include eRapa, under development for Familial Adenoma

    3/27/26 5:00:00 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

    Optimal dose intended for Phase 3 demonstrates statistically significant reduction in lesion growth (31%) versus control at 12 months (p< 0.05)Potential 2X treatment benefit compared to 15% and 22% reductions reported for currently approved therapies at 12 and 24 months, respectivelyNo serious adverse events and no adverse events of special interest related to OCU410 reported to date MALVERN, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced positive 12-month data from the Phase 2 ArMaDa clinical trial evaluating OCU410 (AAV5-RORA), its novel modifier gene

    3/24/26 7:45:00 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APGN
    $BDRX
    $BIOL
    $BIOR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Ocugen with a new price target

    Canaccord Genuity initiated coverage of Ocugen with a rating of Buy and set a new price target of $12.00

    3/17/26 8:33:47 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Oppenheimer initiated coverage on Ocugen with a new price target

    Oppenheimer initiated coverage of Ocugen with a rating of Outperform and set a new price target of $10.00

    3/11/26 8:39:19 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Wedbush initiated coverage on Zura Bio Limited with a new price target

    Wedbush initiated coverage of Zura Bio Limited with a rating of Outperform and set a new price target of $15.00

    2/9/26 6:54:14 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APGN
    $BDRX
    $BIOL
    $BIOR
    SEC Filings

    View All

    SEC Form 10-K filed by Enveric Biosciences Inc.

    10-K - Enveric Biosciences, Inc. (0000890821) (Filer)

    3/27/26 5:27:50 PM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enveric Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Enveric Biosciences, Inc. (0000890821) (Filer)

    3/27/26 5:25:41 PM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 20-F filed by Biodexa Pharmaceuticals plc American Depositary Shs

    20-F - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

    3/27/26 5:09:45 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APGN
    $BDRX
    $BIOL
    $BIOR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Parker Stephen Barry

    3 - Biodexa Pharmaceuticals Plc (0001643918) (Issuer)

    3/20/26 5:19:51 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by Biodexa Pharmaceuticals plc American Depositary Shs

    3 - Biodexa Pharmaceuticals Plc (0001643918) (Issuer)

    3/18/26 9:30:18 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by Biodexa Pharmaceuticals plc American Depositary Shs

    3 - Biodexa Pharmaceuticals Plc (0001643918) (Issuer)

    3/18/26 9:30:20 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APGN
    $BDRX
    $BIOL
    $BIOR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Ai Biotechnology Llc bought $12,500,000 worth of Class A Ordinary Shares (2,000,000 units at $6.25) (SEC Form 4)

    4 - Zura Bio Ltd (0001855644) (Issuer)

    3/2/26 5:55:03 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Fernandes Prabhavathi bought $9,095 worth of shares (10,000 units at $0.91) (SEC Form 4)

    4 - Ocugen, Inc. (0001372299) (Issuer)

    12/2/24 4:15:25 PM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Castillo Kirsten bought $22,848 worth of shares (25,000 units at $0.91), increasing direct ownership by 50% to 75,000 units (SEC Form 4)

    4 - Ocugen, Inc. (0001372299) (Issuer)

    11/26/24 4:50:10 PM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APGN
    $BDRX
    $BIOL
    $BIOR
    Leadership Updates

    Live Leadership Updates

    View All

    Preliminary Results for the Year Ended 31 December 2025

    March 27, 2026 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company" or, together with its subsidiaries, the "Group") Preliminary Results for the Year Ended 31 December 2025 Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, announces its audited preliminary results for the year ended 31 December 2025. For more information, please contact: Biodexa Pharmaceuticals PLC Stephen Stamp, CEO Fiona Sharp, CFOTel: +44 (0)29 2048 0180www.biodexapharma.com About Biodexa The Company's lead development programs include eRapa, under development for Familial Adenoma

    3/27/26 5:00:00 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to Board of Directors

    Zura Bio Limited (NASDAQ:ZURA) ("Zura" or the "Company"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced the appointments of Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to its Board of Directors, effective February 21, 2026. As part of this transition, Neil Graham, M.B.B.S., M.D., M.P.H., will step down from the Board effective the same date. "Mark and Ajay are accomplished immunology executives who have successfully guided innovative biologics from early development through approval and commercialization on a

    2/23/26 6:30:00 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer

    MALVERN, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the appointment of Rita Johnson-Greene as Chief Financial Officer (CFO). "Mrs. Johnson-Greene's diverse background across a variety of strategic roles at organizations representing many facets of the industry make her well-suited to serve as Ocugen's CFO," said Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen. "We look forward to her leadership as we enter into a transformative time at Ocugen, beginning with the submission of the first of three Biologics License Applications (BLAs) this

    2/9/26 7:02:00 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APGN
    $BDRX
    $BIOL
    $BIOR
    Financials

    Live finance-specific insights

    View All

    Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy

    MALVERN, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast with key opinion leaders (KOLs) and Ocugen executive leadership to discuss the full data set from the Phase 2 ArMaDa clinical trial evaluating OCU410 for geographic atrophy (GA), late-stage dry age-related macular degeneration (dAMD) at 8 a.m. EDT on Tuesday, March 24, 2026. KOLs leading the webcast include: Lejla Vajzovic, MD, FASRS, Professor of Ophthalmology, Director of CME-Ophthalmology, Duke University School of Medicine & Chairman, Ocu

    3/23/26 7:02:00 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ocugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2025 Financial Results

    MALVERN, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company's fourth quarter and full year 2025 financial results and provide a business update at 8:30 a.m. ET on Wednesday, March 4, 2026. Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details: Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callersConference ID: 3029428Webcast: Available on the events sec

    2/18/26 7:02:00 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data

    MALVERN, Pa., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast with KOLs and Ocugen executive leadership to discuss data from the first half of patients completing one year since treatment in the OCU410 Phase 2 ArMaDa clinical trial at 8:30 a.m. ET on Thursday, January 15, 2026. Study investigators leading the webcast include: Arshad M. Khanani, MD, MA, FASRS, Director of Clinical Research, and Director of Fellowship at Sierra Eye Associates and Clinical Professor at the University of Nevada, Reno School

    1/13/26 7:00:00 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APGN
    $BDRX
    $BIOL
    $BIOR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Biodexa Pharmaceuticals plc American Depositary Shs

    SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

    11/20/24 11:56:39 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Zura Bio Limited

    SC 13G/A - Zura Bio Ltd (0001855644) (Subject)

    11/14/24 5:52:59 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Biodexa Pharmaceuticals plc American Depositary Shs

    SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

    11/14/24 5:12:47 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care